Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Experimental antiarrhythmic drug reduces death rate in patients with atrial fibrillation

18.02.2009
Results from ATHENA trial published

Results from the ATHENA trial, reported in the 12th February issue of the New England Journal of Medicine, suggest that the (as yet unlicensed) antiarrhythmic drug dronedarone can reduce the incidence of cardiovascular-related hospitalisation or death in patients with atrial fibrillation. The study was performed at more than 550 centres in 37 countries.

The trial, with a mean follow-up of 21 months, randomised 4628 patients with atrial fibrillation and at least one other cardiovascular risk factor to either dronedarone or placebo. Results found 24% fewer deaths or hospitalisations (the primary composite endpoint) in the treatment group than in the placebo – a hazard ratio for treatment of 0.76, p

The ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation have described dronedarone as a derivative of amiodarone (a well established and recommended treatment for atrial fibrillation) under development as an ion-channel blocking drug.

Speaking on behalf of the European Society of Cardiology, Professor Christophe Leclercq from the CHU in Rennes, France, said: “The ATHENA trial shows that dronedarone, a new antiarryhtmic drug similar to amiodarone but with different effects on individual ion channels, reduced the risk of death or hospitalisation for cardiovascular reasons by 36% when compared with placebo. This was in patients without severe heart failure (NYHA class IV) but with paroxysmal or persistent atrial fibrillation or flutter with additional risk factor for death.

“The study found no difference in overall mortality between the two groups but cardiovascular death was significantly reduced with dronedarone by 29%. There was no difference in thyroid-related effects between the two groups. The EURIDIS and ADONIS trials have already shown that dronedarone significantly reduced the recurrence of arrythmias in patients with paroxysmal or persistent atrial fibrillation.

“Dronedarone may thus play a role in the management of atrial arrhythmias in patients with paroxysmal or persistent atrial tachycardias without severe heart failure.”

REFERENCES:

1. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
2. The most common arrhythmia (after a skipped beat) is atrial fibrillation, which affects up to 5 per cent of all adults, mainly the over-65s, and becomes more common with advancing age. Hospitalisations for atrial fibrillation have increased dramatically in recent years.
3. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation can be found at

http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-afib-FT.pdf

Anne Strauss | alfa
Further information:
http://www.escardio.org

More articles from Studies and Analyses:

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

nachricht Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

How gut bacteria can make us ill

18.01.2017 | Life Sciences

On track to heal leukaemia

18.01.2017 | Health and Medicine

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>